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Aims: Pharmacogenetics (PGx) in the UK is currently implemented in secondary care
for a small group of high-risk medicines. However, most prescribing takes place in
primary care, with a large group of medicines influenced by commonly occurring
genetic variations. The goal of this study is to quantitatively estimate the volumes of
medicines impacted by implementation of a population-level, pre-emptive pharmaco-
genetic screening programme for nine genes related to medicines frequently
dispensed in primary care in 2019.
Methods: A large community pharmacy database was analysed to estimate the
national incidence of first prescriptions for 56 PGx drugs used in the UK for the
period 1 January–31 December 2019. These estimated prescription volumes were
combined with phenotype frequency data to estimate the occurrence of actionable
drug–gene interactions (DGI) in daily practice in community pharmacies.
Results: In between 19.1 and 21.1% (n = 5 233 353–5 780 595) of all new
prescriptions for 56 drugs (n = 27 411 288 new prescriptions/year), an actionable
drug–gene interaction (DGI) was present according to the guidelines of the Dutch
Pharmacogenetics Working Group and/or the Clinical Pharmacogenetics Implemen-
tation Consortium. In these cases, the DGI would result in either increased monitor-
ing, guarding against a maximum ceiling dose or an optional or immediate drug/dose
change. An immediate dose adjustment or change in drug regimen accounted for
8.6–9.1% (n = 2 354 058–2 500 283) of these prescriptions.
Conclusions: Actionable drug–gene interactions frequently occur in UK primary care,
with a large opportunity to optimise prescribing.
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1 | BACKGROUND
Pharmacogenetics (PGx) describes the relationship of how varia-
tions in an individual's DNA sequence affect drug metabolism,
transport and response.1 Application of these drug–gene interac-
tions (DGI) can help support prescribing that is personalised to
the individual. This is important for both drug safety and
effectiveness.
The rate at which aberrant phenotypes occur in the general
population is high. Most groups estimate over 95% of the population
carry a genetic variant affecting the prescribing of at least one
drug.2–5 A recent study analysing the phenotype frequencies for
14 pharmacogenes in 487 409 participants in the UK biobank found
99.5% of individuals have a predicted atypical response to at least one
drug.6 Clinical guidelines advising management of these DGI are key
to implementation. The international Clinical Pharmacogenetics
Implementation Consortium (CPIC) and the Dutch Pharmacogenetic
Working Group (DPWG) in the Netherlands have independently
reviewed over 100 DGI and published therapeutic recommendations
for 86 DGI.7 Of these recommendations, a high proportion pertain to
medicines initiated in primary care.
Recently, Kimpton and colleagues analysed prescribing patterns
between 1993 and 2017, in a sample of 648 141 English primary
care patients.8 They found exposure to PGx drugs was high, with
over 80% of patients being exposed to at least one PGx drug, and
58% exposed to two or more PGx drugs over a 20-year period. A
limitation of this study was the inclusion of drugs that do not carry
a published therapeutic recommendation, which means whilst the
study shows exposure is high in primary care, it is unclear what the
impact would be on prescribing.8 In the Netherlands, Bank and col-
leagues analysed dispensing data for initiated medicines in primary
care with a DPWG therapeutic recommendation.9 They combined
this information with population incidence of aberrant phenotypes
to estimate the impact of pre-emptively PGx testing the entire
Dutch population. The authors found that nearly one in four new
prescriptions for 45 PGx drugs had an actionable DGI, with one in
19 new prescriptions requiring a dose adjustment or alternative
drug choice.9
In the UK, implementation of PGx testing in the NHS has
become a source of great interest to policymakers, clinicians and
pharmacists. NHS Improvement and Genomics England have
recently announced plans for a pre-emptive pharmacogenomic test-
ing approach to be implemented by NHS England within the next
10 years.10 PGx test results will be recorded in the patients' medical
records, supporting clinicians and pharmacists in all sectors to make
therapeutic decisions. As shown by Bank and colleagues in the
Netherlands, accessing PGx results in primary care is likely to have
a large impact on prescribing.9 The aim of this paper was therefore
to estimate the impact of PGx testing annually on primary care
within a UK context. To do this, quantitative estimates of the vol-
umes of medicines dispensed annually with a CPIC and/or DPWG
therapeutic recommendation and affected by aberrant phenotypes
were calculated. Furthermore, estimates for the volumes of medi-
cines requiring a dose or drug change, increased monitoring, or
change in long-term management were calculated.
2 | METHODS
2.1 | Overview
The process consisted of five stages relating to those medicines for
which therapeutic recommendations published by DPWG and/or
CPIC are available:
1. Identification and selection of DGI relevant to UK primary care.
2. Classifying therapeutic recommendations and defining the
concept “actionable”.
3. Estimating number of new medicines with DGI initiated in UK
primary care.
4. Estimating frequency of actionable phenotypes for relevant med-
icines initiated in UK primary care.
5. Applying frequency of actionable phenotypes to number of new
medicines to estimate the frequency at which a change in
prescribing or monitoring of medicine is required according to
DPWG and/or CPIC guidelines.
What is already known about the subject?
• Pharmacogenomic information at the point of prescribing
can help improve safety and efficiency of prescribing.
• NHS England plan to embed pharmacogenomics in prac-
tice by 2025.
• Primary care prescribing of pharmacogenomic drugs is
common but impact on prescribing is unknown.
What this study adds?
• Within the UK, approximately 5 780 595 prescriptions
for medicines dispensed annually in primary care have an
actionable drug–gene interaction according to interna-
tional guidelines.
• Four pharmacogenes (CYP2C19, CYP2D6, SLCO1B1,
HLA-B) are responsible for >95% of all drug–gene inter-
actions observed.
• One in 11 new prescriptions for pharmacogenomic medi-
cines dispensed annually in UK primary care require a
direct dose or drug change according to international
guidelines.
• These findings could inform policy makers looking to
implement pharmacogenetic testing in UK primary care.
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2.2 | Approval
The study was confirmed as a service evaluation by the University of
East Anglia Faculty of Medicine and Health Sciences Research Ethics
Committee (Reference: 2019/20-080).
2.3 | Identification and selection of drugs and DGI
relevant to UK primary care
Medicines included in the analysis were those with PGx drug/dosing
guidelines published by the DPWG and/or CPIC. Guidelines published
up to 31 March 2020 were identified through PharmGKB, which
provides an up-to-date repository of gene–drug interactions and
therapeutic recommendations published by DPWG, CPIC and other
organisations.11
Medicines were screened against a set of inclusion/exclusion
criteria using the following UK-based medicine resources:
British National Formulary (BNF),12 Martindale: the complete drug
reference13 and Openprescribing.net.14
Inclusion criteria:
• Licensed in the UK
• Initiated or continued in primary care
Exclusion criteria:
• Specialist medicines requiring long-term monitoring by secondary
care prescribers.
For each drug selected, only a single gene interaction was included for
analysis. Population frequency data for multiple concurrent aberrant
phenotypes were unavailable, and thus to avoid overestimating the
effect of PGx testing for a single drug, the phenotype frequency data
was applied for the most impactful single gene. This was either the
gene associated with phenotypes that led to more “actionable” thera-
peutic recommendations, e.g. choosing the gene with recommenda-
tions for “direct action” over the gene with “indirect action”, or
choosing the gene with the most frequently occurring aberrant
phenotypes in the UK population. For example, the VKORC1 gene
was selected over CYP2C9 and CYP4F2 genes when analysing the
impact of PGx testing on warfarin, because VKORC1 gene aberrant
variants account for a higher percentage of variation in warfarin
dosing (30% vs 18% and 11% respectively)15 and occur more frequently
in European populations compared to CYP2C9 and CYP4F2.16
2.4 | Classifying “actionability” of therapeutic
recommendations
CPIC and DPWG guidelines were reviewed for each selected DGI and
therapeutic recommendations were labelled in a standard format as
shown in Table S1. Where differences between CPIC and DPWG
therapeutic recommendations occurred,17 both recommendations
were considered and estimates for the overall impact were recorded
as a range to reflect this. Additionally, both sets of guidelines were
checked to see whether the therapeutic recommendations were
dependent on specific patient factors, or concomitant medications.
2.5 | Estimating number of new medicines with
DGI initiated in UK primary care
Total volumes of prescriptions for PGx drugs dispensed in primary
care between 01 January 2019 and 31 December 2019 were
extracted from national databases.18–21 Dispensing patterns in a large
UK pharmacy chain database were then analysed to estimate the
proportion of medicines newly initiated as part of the total annual
dispensing volumes for medicines relevant to UK primary care
(Supplementary file 1). To calculate rates, total and newly dispensed
volumes for all relevant PGx drugs between 01 January 2018 and
31 December 2018 were extracted from the dispensing database.
Newly dispensed drug volumes were defined as drugs which were
dispensed for the first time in 12 months to the patient.
To obtain national estimates of new prescriptions for the
56 drugs, these proportions were applied to total primary care
dispensing volumes between 01 January 2019 and 31 December
2019 for England, Scotland, Northern Ireland and Wales.
2.6 | Estimating frequency of actionable
phenotypes for relevant medicines initiated in UK
primary care
Phenotypic frequency data for six genes (CYP2C9, CYP2C19, CYP2D6,
SLCO1B1, TPMT and VKORC1) and three genetic variants
(HLA-B*57:01, HLA-B*15:02 and factor V Leiden) were obtained from
TABLE 1 Therapeutic recommendations assigned “direct action”, “indirect action” and “no action”
Direct action Indirect action No action
Therapeutic recommendation Lower dose required at start therapy Observe status of patient carefully
Higher dose required at start therapy Optional lower dose required at start therapy
Switch to alternate drug at start therapy Optional higher dose required at start therapy
Optional switch at start therapy
Guard against maximum dose
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an anonymised pool of 879 patients at the University of Liverpool, UK,
as part of the “Preemptive Pharmacogenomic Testing for Preventing
Adverse Drug Reactions” (PREPARE) study (Clinical trial.gov identifier:
NCT03093818). The genetic test results for CYP2D6, CYP2C19,
SCLO1B1, TPMT and VKORC1 were translated to actionable
phenotypes (intermediate, poor or ultra-rapid metaboliser) using DPWG
guidelines.22 For the gene CYP2C19, haplotype was translated to pheno-
type (intermediate [activity score 1], intermediate [activity score 1.5],
poor metaboliser), using CPIC guidelines to support application of thera-
peutic recommendation for non-steroidal anti-inflammatories23 (see
Supplementary File 1). Phenotype frequencies for HLA-A*31:01,
HLA-B*15:02 and HLA-B*58:01 were calculated using ethnicity
incidence frequency tables24 matched to UK census data 2011 similar to
the methodology described by Fan and Bousman.25 (Supplementary File
2 contains estimates for UK phenotype incidence used in this study.)
2.7 | Estimating impact
To estimate the potential impact of PGx testing on drugs newly initi-
ated in the UK, the estimated newly initiated prescription volumes of
relevant PGx drugs were multiplied by the percentage incidence of
different actionable phenotypes to obtain estimates for prescription
volumes of PGx drugs dispensed nationally that require a change in
prescribing or monitoring.
2.8 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to PHARMA-
COLOGY, and are permanently archived in the Concise Guide to
PHARMACOLOGY 2019/20.26
3 | RESULTS
3.1 | Identification of relevant PGx drugs to UK
primary care
A total of 56 drugs with 56 unique DGIs were included in the study.
Figure 1 is a flowchart representing the selection process for medi-
cines included in the study.
3.2 | Overall UK results
There were 27 411 287 estimated new prescriptions for 56 PGx drugs
in 2019 (England: 22264390 items, Scotland 2 416 941 items, Wales
1 753 062 items, Northern Ireland 976 894 items). Table 2 shows the
overall estimated newly initiated prescription volumes for 56 PGx drugs
dispensed by community pharmacies in 2019. Table 3 shows the
breakdown of drug volumes per actionable phenotype. It is estimated
that between 5 233 353 and 5 780 595 of these prescriptions had an
actionable therapeutic recommendation according to CPIC and/or
DPWG guidelines. Table 4 shows a breakdown of the estimated volume
ranges of prescriptions dispensed in UK primary care in 2019.
Based on the data presented in this study, between one in four to
one in five new prescriptions for one of these 56 PGx drugs newly initi-
ated in the community requires a therapeutic intervention. Should all
patients in the UK with a new prescription for this selection of drugs
have been pre-emptively genotyped for nine genes (CYP2C19,
CYP2C9, CYP2D6, F5, HLA-A, HLA-B, SLCO1B1, TPMT, VKORC1),
then one in every 11 new prescriptions could be adjusted based on the
genetic result. This frequency is the same across England, Northern
Ireland, Scotland and Wales.
3.3 | Frequency of exposure to PGx drugs by
therapeutic group
Table 5 shows the distribution of newly initiated PGx drugs dispensed
in the UK in 2019 by therapeutic group. The PGx drugs with thera-
peutic recommendations (n = 5 780 595) dispensed to UK patients in
the largest volumes were for weak opioids (47.9%, n = 2 766 128),
antidepressants (30.9%, n = 1 783 362) and proton pump inhibitors
(5.7%, n = 329 300).
For those medicines with a therapeutic recommendation requir-
ing “direct action” (n = 2 500 283), the top three drug classes were
the same but in a different order; antidepressant (49.5%,
n = 1 236 804), weak opioid (15.4%, n = 385 638), proton pump inhib-
itors (13.1%, n = 327 491).
3.4 | Frequency of exposure to PGx drugs by gene
Tables 6 and 7 shows the distribution of newly initiated PGx drugs
dispensed in the UK in 2019 by gene. Of the estimated 5 780 595
medicines with a therapeutic recommendation, four genes accounted
for 95.8% of all DGI: 68.3% CYP2D6 (n = 3 950 129), 20.1%
CYP2C19 (n = 1 159 040), 3.8% HLA-B (n = 222 199) and 3.6%
SLCO1B1 (n = 208 462).
Of the estimated 2 500 283 prescription items dispensed in the
UK with a recommendation for “direct action”, 61.3% (n = 1 531 923)
were affected by the CYP2D6 gene, 25.0% (n = 624 298) were
CYP2C19 gene and 8.3% (n = 208 462) were affected by the
SLCO1B1 gene.
3.5 | Frequency of exposure to PGx drugs by age
Table 8 shows the age distribution of patients exposed to a PGx drug
in 2018. Of the 4 439 352 patients in the community
pharmacy database newly dispensed one of 56 PGx drugs, 61.9%
(n = 2 746 113) were between the ages 19 and 59. In those 0–18 years,
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exposure to an anti-infective PGx drug was most common (34.4%),
whilst those aged between 19 and 49 years were more likely to be
exposed to antidepressants with a DGI. In age groups 50–115 years,
exposure to proton pump inhibitors and analgesia were the most com-
mon sources for PGx exposure.
4 | DISCUSSION
4.1 | Main findings
Our findings demonstrate the high impact PGx testing could have on
medicines prescribed across primary care in the UK. Based on the
frequencies of actionable phenotypes for six genes from 879 patients
and the estimated actionable phenotypes for three genetic variants from
ethnicity census data, we inferred that between 19.1% and 21.1% of
the first prescriptions for these 56 PGx drugs would have an actionable
DGI requiring direct or indirect intervention. If the UK population were
pre-emptively tested for this panel of genes, then an estimated
8.6–9.2% of the first prescriptions for these 56 PGx drugs would require
a direct intervention as per CPIC and/or DPWG guidelines.
The most common newly initiated PGx drugs with an actionable
DGI were for weak opioids like codeine and tramadol, antidepressants
and proton pump inhibitors. Four genes (CYP2D6, CYP2C19, HLA-B
and SCLO1B1) accounted for 95.8% of all drugs initiated with an action-
able DGI. Age demographics within a community pharmacy database
F IGURE 1 Drug–gene interactions (DGIs)
included in study. Flowchart of DGIs and drugs
selection process using Clinical Pharmacogenetics
Implementation Consortium (CPIC) and Dutch
Pharmacogenetics Working Group (DPWG)
guidelines
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TABLE 2 Estimate of annual volume of PGx drugs newly initiated in UK primary care
Drug
Estimate of volumes of PGx medicines newly initiated in primary care (2019)
England Scotland Wales Northern Ireland UK (total)
Acenocoumarol 1107 26 27 5 1165
Allopurinol 280 391 22 658 24 466 7190 334 705
Amitriptylline 1 456 603 136 070 113 825 55 169 1 761 667
Ampicillin_flucloxacillin 4663 243 64 94 5064
Aripiprazole 90 819 5680 7215 2643 106 357
Atomoxetine 12 830 1417 968 829 16 044
Atorvastatin with concomitant CYP inhibitors 102 695 5070 6248 2897 116 910
Azathioprine 43 786 5547 2939 1801 54 073
Carbamazepine 93 188 8277 6371 3252 111 088
Celecoxib 41 410 7904 2087 3957 55 358
Citalopram 1 306 405 101 452 120 505 49 224 1 577 586
Clomipramine 14 210 2139 1193 484 18 026
Clopidogrel 462 092 40 163 30 422 11 663 544 340
Codeine 1 147 510 50 040 45 913 17 054 1 260 517
Codeine_aspirin 72 9 5 2 88
Codeine_paracetamol 2 551 074 465 019 307 277 211 929 3 535 299
Codeine_ibuprofen 99 17 4 8 128
Codeine_paracetamol_buclizine 730 2991 385 259 4365
Codeine_paracetamol_caffeine 490 0 31 2 523
Doxepin 1056 220 70 50 1396
Escitalopram 154 094 9115 4773 11 362 179 344
Estrogen_contraceptives 1 316 077 132 871 64 667 57 844 1 571 459
Flecainide 25 056 1522 1772 380 28 730
Flucloxacillin 2 842 764 323 869 198 383 96 471 3 461 487
Flurbiprofen 0 70 45 38 153
Fluvoxamine 1571 128 92 54 1845
Haloperidol 56 980 4523 3727 2326 67 556
Ibuprofen 584 337 169 678 78 355 41 800 874 170
Ibuprofen_paracetamol 110 0 1 1 112
Imipramine 12 530 2046 618 285 15 479
Lamotrigine 120 310 11 409 7847 4726 144 292
Lansoprazole 2 130 638 126 705 136 903 57 234 2 451 480
Meloxicam 69 546 9345 4278 4425 87 594
Mercaptopurine 4776 813 331 190 6110
Metoprolol 17 253 1532 830 461 20 076
Nortriptylline 80 164 9632 3288 1955 95 039
Omeprazole 3 211 202 364 505 260 405 128 861 3 964 973
Ondansetron 81 088 10 221 4616 10 181 106 106
Oxcarbazepine 5005 342 225 88 5660
Pantoprazole 99 827 4468 4922 9217 118 434
Paroxetine 74 841 6949 7348 2400 91 538
Phenytoin 13 801 1088 831 262 15 982
Piroxicam 1758 201 93 244 2296
Sertraline 2 094 199 170 666 173 404 93 388 2 531 657
Simvastatin 508 662 52 615 42 996 13 184 617 457
(Continues)
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suggest type of PGx drug exposure changes with age. Patients under
50 years were more likely to be exposed to antidepressants and anti-
infectives with DGIs. In the over 50s, PGx exposure was more
frequently attributed to gastrointestinal and analgesic medicines.
Using the community pharmacy database as reference
[Supplementary File 1], we identified the number of unique patients
newly dispensed at least one of the 56 PGx drugs selected in one
year. We then extrapolated this to the national prescription volumes
to estimate between 3 741 848 and 4 133 126 patients annually in
primary care would benefit from PGx testing.
4.2 | Comparison with other studies
Our findings that UK patients are frequently exposed to
pharmacogenomic drugs in primary care is supported by recent
studies from England and the Netherlands. Bank and colleagues in the
Netherlands9 investigated the prescribing of 45 drugs with DPWG
guidelines in primary care. They found that 23.6% of all new prescrip-
tions of these drugs had an actionable DGI, with 5.4% requiring direct
intervention in the form of drug/dose adjustment.
Our analysis showed similar results, but with a higher frequency
of DGI occurrence requiring direct intervention (9.2% vs 5.4%). This is
likely due to differences in methodology. Our analysis included more
PGx drugs, 56 drugs versus 45 drugs, due to the inclusion of both
CPIC and DPWG therapeutic recommendations. Currently, the UK
has no organisation responsible for publishing PGx prescribing guide-
lines. As a result, inclusion of both CPIC and DPWG therapeutic
recommendations provides the broadest interpretation of potential
impact on UK prescribing patterns.
Kimpton and colleagues8 investigated the exposure of 648 141
English primary care patients to 63 drugs over a 25-year period. They
found that three genes (CYP2C19, CYP2D6 and SCLO1B1) accounted
for >95% of the common PGx drugs dispensed. When restricted to
PGx drugs associated with “direct action”, our analysis showed similar
results with the same three genes accounting for 94.6% of PGx drug
dispensing. A broader analysis of our results of all DGI with any
actionable recommendation shows 95.8% DGI are affected by four
genes (CYP2C19, CYP2D6, SLCO1B1, HLA-B). A strength of our
study was the inclusion of phenotype frequency data; therefore our
analysis supports the assertion that testing for CYP2C19, CYP2D6,
SCLO1B1 and HLA-B provides the biggest opportunity to optimise
medicines dispensed in primary care due to the high incidence of
actionable DGI for these genes occurring in the population.
4.3 | Implementation of PGx testing in the UK
NHS England have recently announced plans to adopt a pre-emptive
PGx testing strategy for drug–gene pairs with the most evidence of
clinical and cost-effectiveness.27 The aim is for patients in the next
ten years to be tested for a panel of genes and genetic variants, and
to have these results recorded in their medical records, for healthcare
professionals to access across primary and secondary care.27
Our study demonstrates that population-level PGx testing has a
large impact on the prescribing of medicines in UK primary care, with
approximately 5 780 595 prescriptions for medicines dispensed annually
having an actionable DGI according to CPIC and/or DPWG guidelines.
Of these affected medicines, more than 95% of DGIs were due to vari-
ants in CYP2C19, CYP2D6, SCL01B1 and HLA-B genes. To date, little
has been published on which genes will be tested by the NHS England
pre-emptive PGx testing panel. A pharmacogenomics working group has
been set up by NHS Improvement and Genomics England to review evi-
dence and design a panel accordingly.28 Results from the ongoing
PREPARE study, a multi-centre European randomised controlled trial
investigating if panel PGx testing reduces the incidence of adverse
events and healthcare expenditure,29 will likely influence gene selection
for panel design. The gene panel for the PREPARE study consists of
TABLE 2 (Continued)
Drug
Estimate of volumes of PGx medicines newly initiated in primary care (2019)
England Scotland Wales Northern Ireland UK (total)
Simvastatin_ezetimibe 555 21 18 38 632
Simvastatin_fenofibrate 16 5 0 6 27
Tamoxifen 42 740 4213 2784 1321 51 058
Tenoxicam 28 8 2 2 40
Tramadol 666 669 100 900 43 281 40 733 851 583
Tramadol_paracetamol 6208 325 678 1193 8404
Trimipramine 887 61 59 25 1032
Venlafaxine 289 694 30 099 22 516 24 245 366 554
Voriconazole 137 54 28 2 221
Warfarin 132 250 11 423 12 554 3194 159 421
Zuclopenthixol 7387 577 377 246 8587
Total 22 264 390 2 416 941 1 753 062 976 894 27 411 287
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TABLE 4 Estimation for prescription volumes of primary care medicines in 2019 with CPIC and/or DPWG therapeutic recommendations
Volume of prescriptions with CPIC and/or DPWG guidelines dispensed in UK primary care 2019
Highest estimation Lowest estimation
Direct action 2 500 283 2 354 058
Higher dose required at start therapy 328 086 327 491
Lower dose required at start therapy 912 492 846 005
Switch to alternate drug at start
therapy
1 259 705 1 180 562
Indirect action 3 280 166 2 879 465
Guard maximum daily dose 550 204 137 987
Observe status of patient carefully 2 613 125 2 613 037
Optional lower dose required at start
therapy
119 241 111 325
Optional switch drug at start therapy 5595 1697
TABLE 5 Distribution of newly initiated PGx drugs dispensed in the UK in 2019 by therapeutic group
Therapeutic class
Total volume of PGx drugs
newly dispensed in UK
Total volume of PGx drugs with an
“actionable” therapeutic
recommendation dispensed in UK
Total volume of PGx drugs with direct
action therapeutic recommendation
dispensed in UK
n % n % n %
Analgesic 6 680 630 24.4% 2 909 816 50.3% 418 380 16.7%
NSAIDs 1 019 723 3.7% 143 688 2.5% 32 742 1.3%
Weak opioids 5660,907 20.7% 2 766 128 47.9% 385 638 15.4%
Cardiovascular 1 488 758 5.4% 410 120 7.1% 399 822 16.0%
Antiarrhythmic 28 730 0.1% 14 038 0.2% 13 549 0.5%
Anticoagulant 160 586 0.6% 19 096 0.3% 19 096 0.8%
Antiplatelet 544 340 2.0% 158 715 2.7% 158 715 6.3%
Beta blocker 20 076 0.1% 9809 0.2% 0 0.0%
Statin 735 026 2.7% 208 462 3.6% 208 462 8.3%
Endocrinology 1 571 459 5.7% 64 068 1.1% 64 068 2.6%
Estrogenic contraceptive 1 571 459 5.7% 64 068 1.1% 64 068 2.6%
Gastrointestinal 6 640 993 24.2% 329 300 5.7% 329 300 13.2%
Antiemetic 106 106 0.4% 1809 0.0% 1809 0.1%
Proton pump inhibitor 6 534 887 23.8% 327 491 5.7% 327 491 13.1%
Immunosuppression 60 183 0.2% 5533 0.1% 5533 0.2%
Infections 3 466 772 12.6% 216 494 3.7% 18 0.0%
Antibiotic 3 466 551 12.6% 216 418 3.7% 0 0.0%
Antifungal 221 0.0% 76 0.0% 18 0.0%
Oncology 51 058 0.2% 24 079 0.4% 24 079 1.0%
Psychiatry/neurology 7 116 729 26.0% 1 815 877 31.4% 1 253 775 50.1%
Antidepressant 6 641 163 24.2% 1 783 362 30.9% 1 236 804 49.5%
Antiepileptic 277 022 1.0% 8853 0.2% 8853 0.4%
Antipsychotic 182 500 0.7% 15 822 0.3% 8118 0.3%
Atomoxetine 16 044 0.1% 7840 0.1% 0 0.0%
Other 334 705 1.2% 5308 0.1% 5308 0.2%
Gout 334 705 1.2% 5308 0.1% 5308 0.2%
Total 27 411 287 100.0% 5 780 595 100.0% 2 500 283 100.0%
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13 genes, covering medicine used both in primary and secondary care.30
If a similar panel of genes is adopted by NHS England, then PGx testing
will have a significant effect on prescribing in primary care even if testing
is initiated in other settings. It is key, therefore, that PGx test results are
recorded in patients' medical records, so they are accessible to all rele-
vant healthcare professionals across healthcare settings. Our study
shows pharmacists and GPs will encounter actionable DGI frequently in
UK primary care. It is therefore essential that education and training is
provided to these professions so that PGx can be used to optimise medi-
cines and reduce adverse drug reactions for primary care patients.
4.4 | Study strengths and limitations
This study addresses a key gap in the existing evidence base for the
potential impact of multi-drug pharmacogenomic testing by estimating
quantitatively the volume of prescriptions for medicines dispensed in
UK primary care where prescribing could be optimised by PGx testing.
These findings could help support a nationwide multi-drug
pharmacogenomic testing programme in primary care by highlighting
the annual exposure of patients to the PGx drugs.
A strength of this study is the inclusion of PGx medicines with
CPIC and/or DPWG evidence-based published prescribing guidelines.
Since there are no UK-based PGx prescribing guidelines, this approach
allowed capture of the widest possible outcomes of PGx testing.
Where differences occurred between “actionability” of recommenda-
tion, e.g. one body recommended direct action whilst the other rec-
ommended non-direct action or no action, both scenarios were
included in the analysis to produce a range of volumes for drugs
affected by particular phenotypes, minimising bias.17 Additionally,
inclusion of DGIs with published therapeutic recommendations
allowed for a more granular analysis of the quantitative impact on pre-
scribing nationally. Our study is the first to estimate the impact of
PGx testing using UK phenotype frequency data. A comparison of a
TABLE 6 Estimated volumes of medicines dispensed in 2019 with a CPIC and/or DPWG therapeutic guidelines recommending “direct
action”
Gene











CYP2C19 522 225 25.5% 45 247 21.8% 38 875 24.3% 17 951 20.7% 624 298 25.0%
CYP2C9 28 281 1.4% 5554 2.7% 2637 1.6% 1737 2.0% 38 209 1.5%
CYP2D6 1 240 041 60.6% 132 842 63.9% 99 592 62.2% 59 448 68.5% 1 531 923 61.3%
F5 53 657 2.6% 5417 2.6% 2636 1.6% 2358 2.7% 64 068 2.6%
HLA-A 2444 0.1% 217 0.1% 167 0.1% 85 0.1% 2913 0.1%
HLA-B 4842 0.2% 396 0.2% 414 0.3% 129 0.1% 5781 0.2%
SLCO1B1 173 551 8.5% 16 367 7.9% 13 971 8.7% 4573 5.3% 208 462 8.3%
TPMT 4465 0.2% 585 0.3% 300 0.2% 183 0.2% 5533 0.2%
VKORC1 15 858 0.8% 1361 0.7% 1496 0.9% 381 0.4% 19 096 0.8%
Total 2 045 364 100.0% 207 986 100.0% 160 088 100.0% 86 845 100.0% 2 500 283 100.0%
TABLE 7 Estimated volumes of medicines dispensed in 2019 with a CPIC and/or DPWG therapeutic recommendation
Gene











CYP2C19 966 447 21.0% 36 560 15.7% 79 232 14.5% 76 801 19.8% 1 159 040 20.1%
CYP2C9 102 961 2.2% 7202 3.1% 26 752 4.9% 12 240 3.2% 149 155 2.6%
CYP2D6 3 110 634 67.4% 174 928 75.3% 396 533 72.5% 268 034 69.0% 3 950 129 68.3%
F5 53 657 1.2% 2358 1.0% 5417 1.0% 2636 0.7% 64 068 1.1%
HLA-A 2444 0.1% 85 0.0% 217 0.0% 167 0.0% 2913 0.1%
HLA-B 182 608 4.0% 6158 2.6% 20 630 3.8% 12 803 3.3% 222 199 3.8%
SLCO1B1 173 551 3.8% 4573 2.0% 16 367 3.0% 13 971 3.6% 208 462 3.6%
TPMT 4465 0.1% 183 0.1% 585 0.1% 300 0.1% 5533 0.1%
VKORC1 15 858 0.3% 381 0.2% 1361 0.2% 1496 0.4% 19 096 0.3%
Total 2 045 364 100.0% 207 986 100.0% 160 088 100.0% 86 845 100.0% 2 500 283 100.0%
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recent study analysing frequency of actionable PGx phenotypes of
487 409 participants in the UK biobank showed similar incidence of
phenotypes for CYP2D6, CYP2C19, SCLO1B1, TPMT and VKORC1
as used in our study.6 The frequencies for F5 and HLA-B*57:01 used
in our study are also comparable to other published studies.31,32
For HLA-A*31:01, HLA-B*15:02, HLA-B*58:01, frequency was
calculated based on ethnicity data taken from the UK census
and published phenotype incidence per ethnicity provided by
PharmGKB. There are several limitations to this approach. Firstly,
UK census ethnicity categories differ from CPIC biogeographical
groups. Secondly, the most recently reported UK census data is
from 2011 and is based on self-reported ethnicity. As a result, this
approach may lead to over- or underestimation of the incidence of
these genetic variants in the UK population. However, collectively
these three genetic variants account for only four of the 56 PGx
drugs included in the study.
Our model to estimate the volumes of PGx drugs newly initiated
in primary care has some limitations. Due to the structure of how
dispensing data in the UK are reported by individual countries, data
on annual volumes of medicines dispensed which are newly initiated
is absent. To overcome this challenge, a large community pharmacy
dispensing database was analysed to calculate what percentage of
total medicines dispensed were newly initiated. To do this, we
assumed medicines first dispensed within a one-year time frame in
the community pharmacy database were newly initiated in primary
care. This may be an overestimation as a patient's newly dispensed
medicine could have been dispensed earlier by another pharmacy.
However, targeting only medicines which have been newly initiated
also has its limitations, since there are opportunities to optimise medi-
cines even when they have already been started through PGx testing;
for example, earlier identification of side effects or safeguarding
against maximum dosing.
Additional sources of limitations to consider include the lack of
patient clinical data in our dispensing data sets. For several drugs,
there may an overestimation of effect as therapeutic recommenda-
tions are based on the combination of both genetic results and
patient clinical factors. PGx drugs included in our analysis affected
by these conditions include clopidogrel, omeprazole, lansoprazole,
pantoprazole, and oral hormonal contraceptives.
Furthermore, our analysis included a single gene interaction for
each drug. For 10 of the 56 PGx drugs (amitriptyline, azathioprine,
carbamazepine, clomipramine, doxepin, imipramine, mercaptopurine,
phenytoin, trimipramine and warfarin) included in our analysis,
additional DGIs were excluded. Our methodology therefore gives a
conservative estimate of the impact of PGx testing for these drugs
and may underestimate the overall impact of PGx testing in UK
primary care.
5 | CONCLUSION
In conclusion, this study demonstrates a high incidence of actionable
DGI occurring in UK primary care. A small number of genes account
for the majority of PGx drugs issued annually with an actionable pre-
scribing recommendation. These findings could support health eco-
nomic modelling, by identifying drug–gene pairs for implementation
prioritisation in primary care.
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